← Human Trials & Peer-Reviewed Studies
Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis
Plain-language guide to PMID 15515479 (2004): clinical trial study of Parathyroid Hormone (PTH 1-84).
Key Facts
- PMID
- 15515479
- Journal
- Acta medica Austriaca
- Year
- 2004
- Study type
- Clinical Trial
- Authors
- Nasri H et al. (3 authors)
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a clinical trial.
The influence of parathormone (PTH) on myocardial function as a toxin of uremia is attracting more attention and evaluation because of growing evidence that the effects of PTH on cardiac function may be the most serious consequence of secondary hyperparathyroidism in renal failure.
In this study the researchers aimed to consider the role of the excess PTH in the development of left ventricular hypertrophy (LVH) and its effects on LV ejection fraction in patients with end-stage renal disease under regular hemodialysis.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
This cross-sectional study was done on patients with end-stage renal disease (ESRD) undergoing maintenance hemodialysis treatment.
Hypertensive patients were stratified into stages one to three.
How the Study Was Run
Calcium, phosphorus, alkaline phosphatase and intact PTH (iPTH) were measured.
Echocardiography for left ventricular (LV) hypertrophy and ejection fraction (percent) were done and LV stratified into normal, mild, moderate and severe hypertrophy.
What Was Measured
The influence of parathormone (PTH) on myocardial function as a toxin of uremia is attracting more attention and evaluation because of growing evidence that the effects of PTH on cardiac function may be the most serious consequence of secondary hyperparathyroidism in renal failure.
Topics PubMed links to this paper include Cross-Sectional Studies, Diabetic Nephropathies, Hypertension, Kidney Failure, Chronic, Parathyroid Hormone, Regression Analysis and Renal Dialysis.
What This Means in Plain Language
This is a clinical trial of Parathyroid Hormone (PTH 1-84).
The abstract goes on to report its results in about 14 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2004 (Acta medica Austriaca), a journal based in Austria.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.